Screener
Vera Therapeutics VERA Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by Vera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Vera Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:33 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212143
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $86,011 | $41,278 |
| General and administrative | 39,121 | 15,916 |
| Total operating expenses | 125,132 | 57,194 |
| Loss from operations | (125,132) | (57,194) |
| Other income (expense): | ||
| Interest income | 6,355 | 6,906 |
| Interest expense | (1,823) | (1,792) |
Item 1. Financial Statements
FAQ
- What is Vera Therapeutics's other operating expenses?
- Vera Therapeutics (VERA) reported other operating expenses of $125.13M in Q1 2026.
- How has Vera Therapeutics's other operating expenses changed year-over-year?
- Vera Therapeutics's other operating expenses increased by 118.8% year-over-year, from $57.19M to $125.13M.
- What is the long-term trend for Vera Therapeutics's other operating expenses?
- Over 4 years (2021 to 2025), Vera Therapeutics's other operating expenses has grown at a 74.0% compound annual growth rate (CAGR), from $34.4M to $315.47M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.
Ask your AI about Vera Therapeutics's other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude